ReThink History: Replacement Therapy
Eight episodes on endocrine manipulation in America: testosterone in men, hormone therapy in women, and the twelve months in which the same regulator loosened the warnings on both. In 1889 a distinguished physiologist injected himself with an extract of dog testicles and reported feeling thirty years younger. He was sincere, and he was wrong. The market he opened has never closed. In February 2025 the Food and Drug Administration removed the cardiovascular boxed warning from testosterone; prescribing to American men climbed past its old peak, and a 2026 study found twelve percent had guideline-concordant testing before their first prescription. In February 2026 the same agency removed the boxed warnings from menopausal hormone therapy, correcting a twenty-four-year wrong by a process its own stakeholders had asked it not to use. The argument is not that hormones are good for women and bad for men. A man who loses both testes to cancer is in exactly the position of a woman who loses both ovaries. Replacement, where something is genuinely missing, is good medicine in either body. Enhancement, where nothing is missing, is a different thing wearing the same word. For women the failure was a treatment withheld; for men it is a treatment pushed. Both are the same failure: nobody asked whether anything was missing. This series is history and policy, not medical advice. Nothing in it is a recommendation to start or stop any treatment — that conversation belongs to you and your own clinician. Researched and compiled by Nick Mackenzie. Narrated by AI from a sourced research dossier.
Listen on Apple Podcasts, Spotify, YouTube, or paste the RSS link into any podcast app.
Episodes
Ep 1: The Elixir of Life
In 1889 one of the most distinguished physiologists in Europe injected himself with an extract of dog and guinea-pig testicles and told the Paris Societe de Biologie he felt thirty years younger.
Ep 2: Two Morning Draws
What hypogonadism actually is, how it is actually diagnosed, and why both major guidelines make you come back a second morning.
Ep 3: Is It Low T?
How you build a two-billion-dollar market for a drug most of its buyers do not medically need.
Ep 4: What It Costs
Exogenous testosterone shuts down the signal that tells the testis to work.
Ep 5: The High-T Department of War
On 15 July 2026 the Secretary of War announced mandatory annual testosterone screening for service members thirty and older.
Ep 6: The Supply Line
Take the readiness argument seriously and follow it to the end.
Ep 7: The Twenty-Four Year Detour
On 9 July 2002 the Women's Health Initiative was stopped early.
Ep 8: The Ones Who Were Told No
Premature ovarian insufficiency affects an estimated three to four percent of women, and roughly 300,000 American women a year have both ovaries removed alongside a hysterectomy.
The Invisible Bill
The Payor of Last Resort
The Physician to Soldier Pipeline
The U.S. Public Health Service